Our unique IND engine has helped us identify novel pathways and targets in immuno-oncology and other areas.
Bemarituzumab (also known as FPA144) is a first-in-class FGFR2b antibody in clinical development as a targeted immune therapy for tumors that over-express FGFR2b. There are currently no other FGFR2b-specific antibodies in the clinic. Because it is specific for FGFR2b, it does not affect in normal cell processes, like metabolic regulation, glucose and phosphate regulation.
This antibody is designed to block tumor growth through two distinct mechanisms:
- It binds specifically to FGFR2b and prevents the binding of certain fibroblast growth factors that promote tumor growth
- It has been engineered to drive immune-based killing of tumor cells by antibody-dependent cell-mediated cytotoxicity through the recruitment of natural killer cells
Bemarituzumab is being evaluated in the FGF2b Inhibition in Gastric and Gastroesophageal Junction Cancer Treatment (FIGHT) Phase 1/3 clinical trial, a global registrational study in patients with advanced gastric or gastroesophageal junction cancer whose tumors overexpress FGFR2b or have FGFR2 gene amplification.
We initiated the randomized, controlled Phase 3 portion of the trial in September 2018. The first patient was dosed at a participating investigative site in China, where Zai Lab is responsible for both development and commercialization of bemarituzumab. In addition to China, the FIGHT trial will also be conducted in the U.S., Europe and other countries in Asia, where the incidence of gastric cancer is high.
In December 2017, we announced a collaboration with Zai Lab for the development and commercialization of bemarituzumab in Greater China. Zai Lab will manage the Phase 3 portion of the FIGHT trial in China.